Followers | 72 |
Posts | 4229 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Thursday, April 29, 2021 11:53:29 AM
MindMed has a pretty comprehensive pipeline of drugs they are developing. This pipeline has started to expand more due to their partnerships and acquisitions. Through their partnerships with labs, universities, and researchers, MindMed has exclusive licenses, including DMT, MDMA, LSD, Psilocybin. There are currently four trials going on at University Hospital Basel, and 13 have already been completed giving MindMed some very valuable data to help push their approvals and research along with faster than they otherwise could have. Here’s an overview of their programs, compounds, and trials, along with their stage of development.
Discover:
April 2020, MindMed signed a nice exclusive collaboration deal with University Hospital Basel’s Liechti Lab (some of the most prolific psychedelic researchers). All IP, trial data, and tech that’s developed here are MindMed’s for the foreseeable future. This originally only gave them access to LSD trials and data, but they’ve since upped their game and expanded the deal to include trials and data on MDMA, DMT, MDMA-LSD (candy flipping), and Psilocybin. Any solid discoveries or advancements will be integrated into MindMed’s pipeline. For example, MindMed already gained data from an ongoing P2 LSD-Anxiety trial from UHB.
February 11, 2021, MindMed announced a partnership with MindShift out of Switzerland. This partnership is focused more on developing novel psychedelic compounds to add to their pipeline. This has been a huge trend in the sector. Companies are trying to modify the compounds to be more conducive to the therapeutic process. Lots of talks have been had around taking the “trip” out of the trip. They are basically allowing people to feel the benefits without hallucinating. Their CEO said some compounds have already been identified for development, but there’s not much on what exactly these secret compounds are. However, patents have apparently been filed over these compounds, so if any of you sleuths can find them, it would be much appreciated.
Develop:
Once psychedelic compounds are identified, they’ll move onto this stage. As of now MindMed has a couple big ones in the works which you’ll be able to find more details on in the chart below. The trials of focus right now investigating 18-MC and LSD for different purposes.
Company / Partner Compound Disorder / Purpose Progress / Stage Rights / IP / Data Market Competition
MindMed (Project Layla) 18-MC (ibogaine derivative) Opioid Use Disorder, Withdrawal, and Potentially Other Addictions P2a (Q3 2021) P3 (at the earliest 2023) Provisional patent filings (MindMed Assignee) ATAI has partnered with DemeRX who are working on Ibogaine and Noribogaine therapy for opioid use disorder and are slightly ahead of MMED. Awakn and CYBN are also both looking at compounds for alcoholism.
MindMed (Project Lucy) LSD Anxiety P2b (Second half of 2021) UHB Data Diamond Therapeutics is working on treating anxiety with psilocybin.
MindMed (UHB) Ketanserin Psychedelic Antagonist (The Naloxone of Psychs) P1 (ongoing) MindMed + UHB have filed a patent application preserving worldwide rights Benzos have been used to kill trips so plenty of people say this isn't needed (I disagree)
MindMed (UHB) LSD LSD Cluster Headaches P2 (ongoing) UHB Data and Rights Beckley Psytech is working on similar headache attacks
MindMed (Project Flow) LSD Adult ADD P2a (approval granted Q3 2021) UHB Data and Rights No ongoing trials in other companies investigating this
MindMed LSD Microdosing (focus, creativity, mood, anxiety) (Starting soon) Honestly don't know First ever P2a clinical trial for microdosing LSD. Very little competition this far along
MindMed (UHB) DMT Neurodynamics P1 (Q2 2021) UHB Data and Rights Algernon is looking at DMT for stroke rehabilitation
MindMed (UHB) LSD + MDMA Candy flipping Investigation P1 (Q1 2021) UHB Data and Rights No candy flipping trials have been conducted yet
MindMed (MindShift) Novel Compounds Investigative Launching early (Q1 2022) Patents filed preserving rights to the novel compounds CYBN is likely one of MMED's biggest competitors in this space. They are killing it in the novel compound development.
MindMed has some additional compounds that they plan to develop that there hasn’t been a ton of information posted on. However, they are the assignee of a family of patents in the US, Australia, Canada, Europe, Japan, and New Zealand for psychotherapy using 3-MMC. The disorders it covers are distress, PTSD, generalized anxiety disorder. A lot of other MindMed IP is being held as trade secrets for the time being, so there’s not a lot to say about it at the moment other than they are expanding their pipeline significantly.
Recent MNMD News
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:15:11 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM